• Summit receives FDA clearance for excimer-laser procedure

    The US Food and Drug Administration (FDA) granted Summit Technology (Waltham, MA) clearance to market and sell its excimer-laser system in the USA for phototherapeutic keratectomy (PTK)--the treatment of scars, dystrophies, and other pathologic conditions of the cornea. Such conditions can significantly affect a person`s vision by clouding the cornea and creating an opacity. Conventional treatment involves a corneal transplant, which requires a donor and can cost u¥to $10,000. Though PTK off
    April 1, 1995

    The US Food and Drug Administration (FDA) granted Summit Technology (Waltham, MA) clearance to market and sell its excimer-laser system in the USA for phototherapeutic keratectomy (PTK)--the treatment of scars, dystrophies, and other pathologic conditions of the cornea. Such conditions can significantly affect a person`s vision by clouding the cornea and creating an opacity. Conventional treatment involves a corneal transplant, which requires a donor and can cost u¥to $10,000. Though PTK offers a much smaller potential market than photorefractive keratectomy--another excimer-laser procedure for which Summit and VISX (Santa Clara, CA) are awaiting FDA approval--the FDA`s clearance of the excimer laser for PTK looks to be a sign that this laser is on its way to being approved for all ophthalmic applications.

    Sign up for Laser Focus World Newsletters
    Get the latest news and updates.

    Voice Your Opinion!

    To join the conversation, and become an exclusive member of Laser Focus World, create an account today!